Patents by Inventor Birgitte Schjellerup Wulff

Birgitte Schjellerup Wulff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID COMPOSITION COMPRISING A PYY COMPOUND AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID
    Publication number: 20220280611
    Abstract: The present invention relates to a solid composition comprising a PYY compound and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.
    Type: Application
    Filed: August 6, 2020
    Publication date: September 8, 2022
    Inventors: Andreas Vegge, Birgitte Schjellerup Wulff, Birgitte Nissen, Soeren Oestergaard, Betty Lomstein Pedersen
  • HPYY(1-36) having a beta-homoarginine substitution at position 35
    Patent number: 10583172
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: March 10, 2020
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff
  • Selective PYY compounds and uses thereof
    Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Selective PYY compounds and uses thereof
    Patent number: 10005824
    Abstract: The invention relates to PYY compounds with the amino acid modifications 7Lys, 30Trp, and 31Leu, and in addition to these, 22Ile and/or 28Tyr, and derivatives thereof. The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: June 26, 2018
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Carsten Jessen, Birgitte Schjellerup Wulff, Annika Sanfridson
  • SELECTIVE PYY COMPOUNDS AND USES THEREOF
    Publication number: 20170313750
    Abstract: The invention relates to PYY compounds with the amino acid modifications 7Lys, 30Trp, and 31Leu, and in addition to these, 22Ile and/or 28Tyr, and derivatives thereof. The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: June 28, 2017
    Publication date: November 2, 2017
    Inventors: Soeren Oestergaard, Carsten Jessen, Birgitte Schjellerup Wulff, Annika Sanfridson
  • SELECTIVE PYY COMPOUNDS AND USES THEREOF
    Publication number: 20160289283
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: October 6, 2016
    Applicant: Novo Nordisk
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • HPYY(1-36) Having a Beta-Homoarginine Substitution at Position 35
    Publication number: 20160263197
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 35 of hPYY(1-36) substituted with beta-homoarginine and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: September 15, 2016
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff
  • Selective PYY compounds and uses thereof
    Patent number: 9085637
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: July 21, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Selective PYY compounds and uses thereof
    Publication number: 20150152150
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Application
    Filed: November 13, 2014
    Publication date: June 4, 2015
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Peptides for Treatment of Obesity
    Publication number: 20130012432
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: February 28, 2011
    Publication date: January 10, 2013
    Applicant: Novo Nordisk A/S
    Inventors: Kilian Waldemar Conde-Frieboes, Jane Spetzler, Ulrich Sensfuss, Birgitte Schjellerup Wulff, Henning Thoegersen, Jens Christian Norrild
  • Peptides for Treatment of Obesity
    Publication number: 20120021973
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: November 24, 2009
    Publication date: January 26, 2012
    Applicant: Novo Nordisk A/S
    Inventors: Jesper F. Lau, Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Birgitte Schjellerup Wulff
  • Use of GLP-1 Peptides
    Publication number: 20110028391
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: October 15, 2010
    Publication date: February 3, 2011
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Peptides for Treatment of Obesity
    Publication number: 20100173835
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: November 25, 2009
    Publication date: July 8, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jesper Lau, Ulrich Sensfuss, Kilian Waldemar Conde-Frieboes, Birgitte Schjellerup Wulff
  • Use of GLP-1 Peptides
    Publication number: 20100113363
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: January 4, 2010
    Publication date: May 6, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
    Publication number: 20100022446
    Abstract: The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.
    Type: Application
    Filed: January 17, 2008
    Publication date: January 28, 2010
    Applicant: Novo Nordisk A/S
    Inventors: Birgitte Schjellerup Wulff, Kirsten Raun, Birgit Sehested Hansen
  • Use of GLP-1 Peptides
    Publication number: 20090149387
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: February 12, 2009
    Publication date: June 11, 2009
    Applicant: Novo Nordisk A/S
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Melanocortin receptor agonists
    Patent number: 7517854
    Abstract: Small cyclic peptides of the formula X1-X2-X3-X4-X5-X6-X7-R1 comprising 7-12 amino acid residues are provided. Said peptides are MC4 receptor agonists, and thus useful in the treatment of obesity and related diseases.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: April 14, 2009
    Assignee: Novo Nordisk A/S
    Inventors: Kilian Waldemar Conde-Frieboes, Ulrich Sensfuss, Kjeld Madsen, Nils Langeland Johansen, Leif Christensen, Thomas Kruse Hansen, Birgitte Schjellerup Wulff
  • Substituted imidazoles, their preparation and use
    Patent number: 6908926
    Abstract: Disclosed is a novel class of substituted imidazole compounds, pharmaceutical compositions containing them and uses of these compounds in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, these compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial. These imidazoles compounds have the formula I wherein R1, R2, R3, R4, R5, R6, A, X, Y and Z are as defined in the specification.
    Type: Grant
    Filed: April 12, 2000
    Date of Patent: June 21, 2005
    Assignee: Novo Nordisk A/S
    Inventors: Florencio Zaragoza Dörwald, Knud Erik Andersen, Tine Krogh Jørgensen, Bernd Peschke, Birgitte Schjellerup Wulff, Ingrid Pettersson, Klaus Rudolf, Dirk Stenkamp, Rudolf Hurnaus, Stephan Georg Müller, Bernd Krist
  • Use of GLP-1 peptides
    Publication number: 20030232754
    Abstract: GLP-1(1-45) or a fragment or an analogue thereof can be used in the preparation of a medicament for peripheral administration in the suppression of appetite or induction of satiety.
    Type: Application
    Filed: March 6, 2003
    Publication date: December 18, 2003
    Inventors: Jens Juul Holst, Arne Vernon Astrup, Martin Edward Judge, Liselotte Bjerre Knudsen, Lars Thim, Birgitte Schjellerup Wulff
  • Use of a pharmaceutical composition comprising an appetite-suppressing peptide
    Patent number: 5912229
    Abstract: The present invention relates to appetite-suppressing peptides or an appetite-suppressing peptide-containing fraction for the treatment of obesity or type II diabetes.
    Type: Grant
    Filed: February 28, 1997
    Date of Patent: June 15, 1999
    Assignee: Novo Nordisk Als
    Inventors: Lars Thim, Birgitte Schjellerup Wulff, Martin Edward Judge, Ole Dragsbaek Madsen, Jens Juul Holst